Back to results
US 9,809,654 B2Granted
Targeted CD1d molecules
AssigneeVaccinex, Inc.
InventorsBruno Robert, Alena Donda, Valerie Cesson, Jean-Pierre Mach, Maurice Zauderer
Life of this patent
Estimating the term…
Abstract
The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a β2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.
Claims29
A compound comprising:
- (a) a soluble CD1d complex comprising:
- i) a CD1d molecule or antigen-binding fragment thereof;
- ii) a β2-microglobulin molecule or fragment thereof;
- and
- iii) a stimulatory glycolipid antigen bound in the antigen binding groove of the CD1d molecule or antigen-binding fragment thereof;
- and
- (b) an antibody or an antigen-binding fragment thereof specific for a cell surface marker of a tumor cell;
- wherein said CD1d complex is linked to said antibody or fragment thereof;
- and wherein said compound stimulates the activation of the cytolytic activity of NKT cells.
6 more elements
Dependencies are inferred from the claim text.